Literature DB >> 27664568

Osteomalacia induced by long-term low-dose adefovir dipivoxil: Clinical characteristics and genetic predictors.

Zhe Wei1, Jin-Wei He1, Wen-Zhen Fu1, Zhen-Lin Zhang2.   

Abstract

CONTEXT: Adefovir dipivoxil (ADV) was an important cause of adult-onset hypophosphatemic osteomalacia. However, its clinical characteristics and mechanisms have not been well defined.
OBJECTIVE: The objective of the study was to summarize the clinical characteristics of ADV-induced osteomalacia and to explore the association between ADV-associated tubulopathy and polymorphisms in genes encoding drug transporters. DESIGN, SETTING, PATIENTS, AND MAIN OUTCOME MEASURE: Seventy-six affected patients were clinically studied. The SLC22A6 and ABCC2 genes were screened and compared with healthy people from the HapMap.
RESULTS: Hypophosphatemia, high serum alkaline phosphatase (ALP) levels, hypouricemia, nondiabetic glycosuria, proteinuria, metabolic acidosis and high bone turnover markers were the main metabolic characteristics. Fractures and pseudofractures occurred in 39 patients. Stopping ADV administration, supplementing calcitriol and calcium was effective during the follow-up period. Single SNP analysis revealed a higher percentage of the G/A genotype at c.2934 in exon 22 of the ABCC2 gene (rs3740070) in patients than in healthy people (12% [7 of 58 patients] vs. 0% [0 of 45 patients]; P=0.017), while there was no subject with homozygosity for the A allele at c.2934.
CONCLUSIONS: ADV can be nephrotoxic at a conventional dosage. The G/A genotype at c.2934 of the ABCC2 gene may be a predictor of patients at greater risk for developing ADV-associated tubulopathy. Larger case-control studies are needed to further verify this finding.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ABCC2; Adefovir dipivoxil; Clinical characteristic; Hypophosphatemic osteomalacia; Risk genotype; SLC22A6

Mesh:

Substances:

Year:  2016        PMID: 27664568     DOI: 10.1016/j.bone.2016.09.017

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  6 in total

1.  Drug-induced osteoporosis/osteomalacia: analysis in the French and Spanish pharmacovigilance databases.

Authors:  Quentin Dardonville; Esther Salguiero; Vanessa Rousseau; Leila Chebane; Jean Luc Faillie; Sophie Gautier; Jean Louis Montastruc; Alfonso Carvajal; Haleh Bagheri
Journal:  Eur J Clin Pharmacol       Date:  2019-08-29       Impact factor: 2.953

Review 2.  Drug-Induced Hypophosphatemia: Current Insights.

Authors:  Efstathia Megapanou; Matilda Florentin; Haralampos Milionis; Moses Elisaf; George Liamis
Journal:  Drug Saf       Date:  2020-03       Impact factor: 5.606

3.  Low-dose adefovir dipivoxil-induced hypophosphatemia osteomalacia in five chronic hepatitis B virus-infected patients. Is low-dose adefovir dipivoxil-induced nephrotoxicity completely reversible?

Authors:  Yan-Ying Qian; Zhi-Juan Dai; Lu-Ya Ruan; You-Jin Pan; Jian Jin; Meng-Te Shi; Yao-Xin Zhu; Chao-Ming Wu
Journal:  Drug Des Devel Ther       Date:  2019-04-10       Impact factor: 4.162

4.  Cross-sectional retrospective analysis of clinical characteristics of chronic hepatitis B patients with oral antiviral treatment in eastern China.

Authors:  Jueqing Gu; Guodong Yu; Xiaoli Zhang; Shanyan Zhang; Huan Cai; Chanyuan Ye; Yida Yang; Dezhou Li; Zhaowei Tong; Huajiang Shen; Huazhong Chen; Feng Ding; Xijie Lai; Junyan Liu; Meiling Xu; Weiti Wu
Journal:  Virol J       Date:  2021-01-13       Impact factor: 4.099

5.  Clinical features of hypophosphatemic osteomalacia induced by long-term low-dose adefovir dipivoxil.

Authors:  Sheng Zhu; Yu-Hui Yang; Rong-Wei Gao; Ran Li; Yu-Zhen Zou; Lei Feng; Bo Zhang
Journal:  Drug Des Devel Ther       Date:  2017-12-27       Impact factor: 4.162

6.  Adefovir dipivoxil induced hypophosphatemic osteomalacia in chronic hepatitis B: a comparative study of Chinese and foreign case series.

Authors:  Nan Chen; Jian-Bo Zhang; Qiujie Zhang; Yun-Peng Zhao; Li-Yan Li; Li-Wei Liu; Fei Yu; Xin Yu; Tao Peng; Kuan-Xiao Tang
Journal:  BMC Pharmacol Toxicol       Date:  2018-05-16       Impact factor: 2.483

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.